<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Intern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Intern. Med</journal-id>
      <journal-id journal-id-type="doi">10.2169/internalmedicine.56.7562</journal-id>
      <journal-title-group>
        <journal-title>Internal Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0918-2918</issn>
      <issn pub-type="epub">1349-7235</issn>
      <publisher>
        <publisher-name>The Japanese Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28090046</article-id>
      <article-id pub-id-type="pmc">5337461</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>An Isolated Case of Late-onset Amyloidogenic Transthyretin Type Familial Amyloid Polyneuropathy Associated with a Mutant Transthyretin Substituting Methionine for Valine at Position 30 Showing Latent Progressive Cardiac Involvement Confirmed by Serial Annual Electrocardiograms</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sato</surname>
            <given-names>Chikako</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takaya</surname>
            <given-names>Tomofumi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mori</surname>
            <given-names>Shumpei</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hasegawa</surname>
            <given-names>Kohei</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soga</surname>
            <given-names>Fumitaka</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanaka</surname>
            <given-names>Hidekazu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Watanabe</surname>
            <given-names>Yoshiaki</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nishii</surname>
            <given-names>Tatsuya</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kono</surname>
            <given-names>Atsushi K.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morinaga</surname>
            <given-names>Yukiko</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishibashi-Ueda</surname>
            <given-names>Hatsue</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hirata</surname>
            <given-names>Ken-ichi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan</aff>
        <aff id="aff2"><label>2</label>Department of Radiology, Kobe University Graduate School of Medicine, Japan</aff>
        <aff id="aff3"><label>3</label>Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Japan</aff>
        <aff id="aff4"><label>4</label>Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Japan</aff>
      </contrib-group>
      <author-notes>
        <fn>
          <p>Correspondence to Dr.&#x3000;Tomofumi Takaya, <email>toto54@hotmail.com</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>1</month>
        <year>2017</year>
      </pub-date>
      <volume>56</volume>
      <issue>2</issue>
      <fpage>163</fpage>
      <lpage>168</lpage>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>4</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>5</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p><!--CREATIVE COMMONS-->The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Late-onset amyloidogenic transthyretin (ATTR) type familial amyloid polyneuropathy (FAP) shows features distinct from those of early-onset hereditary ATTR type FAP. We herein describe an asymptomatic 68-year-old man with late-onset ATTR type FAP whose serial annual electrocardiograms demonstrated progressive left bundle branch block. Latent but severe cardiac involvement seems to be one feature of late-onset ATTR type FAP, similar to senile systemic amyloidosis (SSA). Early differential diagnosis of late-onset ATTR type FAP from SSA is important because, currently, only the former has new therapeutic options available in Japan. The present case report, therefore, highlights the necessity of careful observation for periodic electrocardiograms. </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>amyloidogenic transthyretin</kwd>
        <kwd>cardiac amyloidosis</kwd>
        <kwd>electrocardiogram</kwd>
        <kwd>familial amyloid polyneuropathy</kwd>
        <kwd>senile systemic amyloidosis</kwd>
        <kwd>Val30Met</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Amyloidogenic transthyretin (ATTR) type familial amyloid polyneuropathy (FAP) associated with a mutant transthyretin substituting methionine for valine at position 30 (Val30Met) is the most common type of hereditary FAP, with special endemic foci in Arao City and Ogawa Village in Japan. In contrast, sporadic late-onset patients with ATTR type FAP associated with Val30Met, with no apparent family history or relationship with other families in the endemic focus, has been reported all over Japan (<xref rid="B1" ref-type="bibr">1</xref>). We herein describe a case of a 68-year-old man diagnosed with late-onset ATTR type FAP. Although he had no cardiac symptoms, his serial annual electrocardiograms (ECGs) showed the gradual progression of cardiac involvement during an asymptomatic stage over eight years.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 68-year-old man with diabetes mellitus was referred to our hospital for further examination of abnormal ECG and left ventricular hypertrophy with decreased left ventricular contractility. He had no family history of cardiac disease. On admission, he had no clinical symptoms of heart failure and was classified as New York Heart Association Class I. No cardiac murmur or respiratory crackles were audible. His blood pressure was 120/60 mmHg with a regular pulse rate of 72 beats/min. A neurological examination revealed impairment of pain and temperature sensation in the distal lower limbs. Chest radiography showed cardiomegaly (cardiothoracic ratio, 56.5%) without congestion or pleural effusion. He had undergone an annual routine ECGs for 8 years at the previous clinic, except in 2010 and 2014 (<xref ref-type="fig" rid="g001">Fig. 1</xref>). In 2008, a QS-wave in V1 and rS-wave in V2 were observed without QRS axis deviation and prolongation in QRS width (93 ms). Incomplete left bundle branch block with left axis deviation and precordial QS-waves appeared in 2009 (QRS width, 116 ms) and progressed to complete left bundle branch block in 2011 (QRS width, 129 ms). A markedly notched QRS in aVL was observed from 2013. The QRS width further increased to 144 ms on admission in 2015. Furthermore, the PR interval widened from 169 ms to 207 ms over 8 years. The laboratory findings indicated mild renal dysfunction (estimated glomerular filtration rate, 51.1 mL/min/1.73 m<sup>2</sup>). The serum brain natriuretic peptide level was elevated at 198.65 pg/mL. Primary light-chain (AL) amyloidosis and Fabry disease were unlikely based on the blood results and urinalysis (<xref ref-type="table" rid="t001">Table</xref>). Typical M-peak was not detected on serum protein electrophoresis. He had no proteinuria, including Bence-Jones protein. The serum &#x3BA;-light chain and &#x3BB;-light chain were all in the normal range, as revealed by immunoelectrophoresis. The &#x3B1;-galactosidase and pyruvic acid levels were within the reference range (102.2 nmol/mg/protein/h and 0.37 mg/dL, respectively). The level of serum transthyretin was 19.2 mg/dL, which was decreased. Echocardiography showed concentric left ventricular hypertrophy (septal wall end-diastolic thickness, 17 mm; inferolateral wall end-diastolic thickness, 19 mm). The ejection fraction had slightly decreased (51%) in 2013 and deteriorated to 41% in 2015. Right ventricular hypertrophy and a small amount of pericardial effusion anterior to the right ventricle were also noted (<xref ref-type="fig" rid="g002">Fig. 2</xref>). Transmitral Doppler inflow patterns (E/A, 1.3) showed pseudo-normalization, and tissue Doppler velocity at the mitral annulus (e', 3.2 cm/s) suggested severely impaired left ventricular relaxation. Late gadolinium-enhanced cardiac magnetic resonance imaging (MRI) showed a characteristic global subendocardial and transmural pattern of myocardial late gadolinium enhancement in the thickened wall of both ventricles (<xref ref-type="fig" rid="g003">Fig. 3A</xref>). <sup>99m</sup>Tc-pyrophosphate scintigraphy revealed diffuse accumulation in the entire myocardium (<xref ref-type="fig" rid="g003">Fig. 3B</xref>). Coronary angiography showed an intact coronary artery. The patient was hemodynamically compensated, as revealed on right heart catheterization, which showed that the mean pulmonary capillary wedge pressure was 14 mmHg, the pulmonary artery pressure was 32/14 mmHg, and the mean right atrial pressure was 6 mmHg. The cardiac index, as measured with a standard thermodilution method, was also preserved at 2.6 L/min/m<sup>2</sup>. Endomyocardial biopsy was avoided because of the left bundle branch block. Instead, colonal biopsy was performed, which showed amyloid deposits on the submucosal arterioles stained by direct fast scarlet (<xref ref-type="fig" rid="g004">Fig. 4A</xref>), showing apple green birefringence (<xref ref-type="fig" rid="g004">Fig. 4B</xref>). Immunohistochemical staining for ATTR was positive (<xref ref-type="fig" rid="g004">Fig. 4C</xref>).</p>
      <fig id="g001" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>12-Lead electrocardiogram for 8 years. Incomplete left bundle branch block appeared in 2009 and progressed to complete left bundle branch block in 2011. The QRS width further increased in 2015. The PR interval also widened over 8 years.</p>
        </caption>
        <graphic xlink:href="1349-7235-56-0163-g001"/>
      </fig>
      <table-wrap id="t001" orientation="portrait" position="float">
        <label>Table.</label>
        <caption>
          <p>Laboratory Data.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Peripheral blood</bold>
              </td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">
                <bold>Electrophoresis</bold>
              </td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> White blood cells</td>
              <td align="right" rowspan="1" colspan="1">4,100 /&#x3BC;L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Albumin</td>
              <td align="right" rowspan="1" colspan="1">61.9%</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Red blood cells</td>
              <td align="right" rowspan="1" colspan="1">412&#xD7;10<sup>4</sup>/&#x3BC;L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> &#x3B1;1-globulin</td>
              <td align="right" rowspan="1" colspan="1">2.9%</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hemoglobin</td>
              <td align="right" rowspan="1" colspan="1">12.7 g/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> &#x3B1;2-globulin</td>
              <td align="right" rowspan="1" colspan="1">8.2%</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hematocrit</td>
              <td align="right" rowspan="1" colspan="1">38.9%</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> &#x3B2;-globulin</td>
              <td align="right" rowspan="1" colspan="1">8.8%</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Platelets</td>
              <td align="right" rowspan="1" colspan="1">17&#xD7;10<sup>4</sup> /&#x3BC;L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> &#x3B3;-globulin</td>
              <td align="right" rowspan="1" colspan="1">18.2%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Biochemistry</bold>
              </td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1">
                <bold>Serology</bold>
              </td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Sodium</td>
              <td align="right" rowspan="1" colspan="1">137 mEq/L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Immunoglobulin G</td>
              <td align="right" rowspan="1" colspan="1">1,145 mg/dL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Potassium</td>
              <td align="right" rowspan="1" colspan="1">4.4 mEq/L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Immunoglobulin A</td>
              <td align="right" rowspan="1" colspan="1">149 mg/dL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Chloride</td>
              <td align="right" rowspan="1" colspan="1">102 mEq/L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Immunoglobulin M</td>
              <td align="right" rowspan="1" colspan="1">90 mg/dL</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Calcium</td>
              <td align="right" rowspan="1" colspan="1">8.8 mg/dL</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Urea nitrogen</td>
              <td align="right" rowspan="1" colspan="1">14.3 mg/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> &#x3B2;2-microglobulin</td>
              <td align="right" rowspan="1" colspan="1">2.1 mg/L</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Serum creatinine</td>
              <td align="right" rowspan="1" colspan="1">1.12 mg/dL</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Estimated glomerular filtration rate</td>
              <td align="right" rowspan="1" colspan="1">51.1 mL/min/1.73m<sup>2</sup></td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> M protein (Immunofixation)</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Uric acid</td>
              <td align="right" rowspan="1" colspan="1">5.5 mg/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Free light chain (&#x3BA;)</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Total protein</td>
              <td align="right" rowspan="1" colspan="1"> 5.9 g/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Free light chain (&#x3BB;)</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Serum albumin</td>
              <td align="right" rowspan="1" colspan="1">3.5 g/dL</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Asparate aminotransferase</td>
              <td align="right" rowspan="1" colspan="1">25 IU/L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hepatitis B virus antigen</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Alanine aminotransferase</td>
              <td align="right" rowspan="1" colspan="1">32 IU/L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hepatitis C virus antibody</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Alkaline phosphate</td>
              <td align="right" rowspan="1" colspan="1">183 IU/L</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Creatine kinase</td>
              <td align="right" rowspan="1" colspan="1">269 IU/L</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> White blood cell &#x3B1;-galactosidase A activity</td>
              <td align="right" rowspan="1" colspan="1">102.2 nmol/mg protein/h</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Creatine kinase MB</td>
              <td align="right" rowspan="1" colspan="1">4 IU/L</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Lactate dehydrogenase</td>
              <td align="right" rowspan="1" colspan="1">184 IU/L</td>
              <td rowspan="1" colspan="1">
                <bold>Urinalysis</bold>
              </td>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Pyruvic acid</td>
              <td align="right" rowspan="1" colspan="1">0.37 mg/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Protein (qualitative)</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Serum amyloid A</td>
              <td align="right" rowspan="1" colspan="1">&lt;5 &#x3BC;g/mL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Glucose</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Transthyretin</td>
              <td align="right" rowspan="1" colspan="1">19.2 mg/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Urinary red blood cells</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Total cholesterol</td>
              <td align="right" rowspan="1" colspan="1">189 mg/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Granular casts</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Triglycerides</td>
              <td align="right" rowspan="1" colspan="1">50 mg/dL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Fatty casts</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Brain natriuretic peptide</td>
              <td align="right" rowspan="1" colspan="1">198.7 pg/mL</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Bence-Jones protein (Immunofixation)</td>
              <td align="right" rowspan="1" colspan="1">(-)</td>
            </tr>
            <tr>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Hemoglobin A1c</td>
              <td align="right" rowspan="1" colspan="1">7.1%</td>
              <td style="padding-left:1em;" rowspan="1" colspan="1"> Protein (quantitative)</td>
              <td align="right" rowspan="1" colspan="1">&lt;3 mg/dL</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="g002" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Transthoracic echocardiography on admission. Transthoracic echocardiography showed concentric biventricular hypertrophy. A small amount of pericardial effusion was observed anterior to the right ventricle.</p>
        </caption>
        <graphic xlink:href="1349-7235-56-0163-g002"/>
      </fig>
      <fig id="g003" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>A: Late gadolinium-enhanced cardiac magnetic resonance imaging. Characteristic global subendocardial and transmural pattern of myocardial late gadolinium enhancement is shown in the thickened wall of both ventricles, since the contrast agent distributed to the extracellular space expanded by amyloid infiltration. Note that, in cardiac amyloidosis, the blood pool is abnormally dark (white star), possibly reflecting fast blood pool washout of the contrast media. B: The <sup>99</sup><sup>m</sup>Tc-pyrophosphate scintigraphic findings. Diffuse cardiac accumulation of <sup>99</sup><sup>m</sup>Tc-pyrophosphate was observed.</p>
        </caption>
        <graphic xlink:href="1349-7235-56-0163-g003"/>
      </fig>
      <fig id="g004" orientation="portrait" position="float">
        <label>Figure 4.</label>
        <caption>
          <p>The pathological findings of a colonal specimen. A colonal biopsy specimen by colon fiber shows amyloid deposits on the submucosal arterioles stained by direct fast scarlet (A), showing apple green birefringence (B). Immunohistochemical staining for amyloidogenic transthyretin was positive (C).</p>
        </caption>
        <graphic xlink:href="1349-7235-56-0163-g004"/>
      </fig>
      <p>Contrary to our initial expectations that cardiac predominant involvement in this aged man would indicate senile systemic amyloidosis (SSA), a transthyretin gene analysis by direct nucleotide sequencing confirmed a diagnosis of late-onset ATTR type FAP associated with Val30Met. Administration of tafamidis, a novel drug for ATTR type FAP, was initiated for his neurological symptoms.</p>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>In general, cardiac amyloidoses involve three main systemic types: AL amyloidosis, hereditary ATTR type FAP, and SSA (<xref rid="B2" ref-type="bibr">2</xref>). We herein report an isolated case of late-onset ATTR type FAP associated with Val30Met showing latent and progressive cardiac involvement proven by serial ECGs.</p>
      <p>ATTR type FAP is a form of hereditary systemic amyloidosis characterized by infiltration of mutant transthyretin. Typical hereditary ATTR type FAP is usually early-onset (30-40 years), showing autosomal dominant inheritance with a high rate of penetrance, concentration in endemic foci (Arao City and Ogawa Village), and predominant loss of superficial sensation and severe autonomic dysfunction (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). The occurrence of ATTR type FAP is similar between men and women. In contrast, the clinical features of isolated cases of late-onset ATTR type FAP associated with Val30Met involve clinical onset at the age of 50 or later without family history or kinship associated with endemic foci, sensorimotor complaints in the legs as an initial symptom, parallel involvement of superficial and deep sensation, mild autonomic dysfunction, and marked male predominance (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>).</p>
      <p>SSA is characterized by infiltration of wild-type ATTR. Cardiac involvement is frequent, and carpal tunnel syndrome might precede the cardiac involvement (<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>). The typical onset is after the age of 70, with strong male predominance (<xref rid="B6" ref-type="bibr">6</xref>).</p>
      <p>Late-onset ATTR type FAP appears to have common clinical characteristics with SSA, in that both mainly occur in aged men and frequently show cardiac involvement (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). It is critical to make the differential diagnosis of late-onset ATTR type FAP and SSA, because ATTR type FAP currently has therapeutic options, such as liver transplantation and some new medications. Since ECG, present imaging modalities, and tissue biopsy cannot differentiate mutant ATTR from wild-type ATTR, transthyretin gene analysis or mass spectrometry is necessary for a definitive diagnosis (<xref rid="B6" ref-type="bibr">6</xref>).</p>
      <p>Aging is a significant factor in amyloid deposition in the myocardium. Late-onset ATTR type FAP, therefore, would be more prone to develop cardiac amyloidosis than early-onset hereditary ATTR type FAP (<xref rid="B4" ref-type="bibr">4</xref>). Accordingly, latent progressive conduction disturbance seems to be a feature of late-onset ATTR type FAP associated with Val30Met, as first demonstrated in the case of a 52-year-old man by Takigawa et al. (<xref rid="B3" ref-type="bibr">3</xref>). They observed 5 years of gradually progressive left anterior fascicle block before the appearance of complete left bundle branch block (<xref rid="B3" ref-type="bibr">3</xref>). The present case showed good agreement with their case. In contrast, although neither patient had symptoms of heart failure, more progressive impairment of the cardiac conduction system was observed in the present case; incomplete left bundle branch block progressed to complete left bundle branch block within 2 years, with further widening of the QRS complex even after the occurrence of complete left bundle branch block. Furthermore, our case showed more advanced myocardial involvement, as revealed by a thicker left ventricular wall (14-15 mm vs. 17-19 mm), lower left ventricular ejection fraction (56% vs. 41%), and larger extent of late gadolinium enhancement (subendocardial vs. transmural).</p>
      <p>As observed in the present case, Buxbaum et al. demonstrated lower serum transthyretin concentrations in carriers of ATTR type FAP associated with Val30Met (<xref rid="B7" ref-type="bibr">7</xref>), possibly reflecting the consumption of transthyretin into amyloid fibril (<xref rid="B6" ref-type="bibr">6</xref>).</p>
      <p>We avoided endomyocardial tissue biopsy because of the complete left bundle branch block. Instead, gastrointestinal tissue biopsy successfully revealed the amyloid deposit. Considering the frequently observed conduction disturbances in patients with cardiac amyloidosis (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>), gastrointestinal tissue biopsy or subcutaneous abdominal fat tissue aspiration are safer and preferable to endomyocardial tissue biopsy (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B8" ref-type="bibr">8</xref>).</p>
      <p>There are feasible methods for distinguishing ATTR amyloidosis from AL amyloidosis. Left ventricular wall thickness has been reported to be greater in ATTR amyloidosis, typically 15-18 mm, compared with 13-15 mm in AL amyloidosis (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B6" ref-type="bibr">6</xref>). In cardiac MRI, ATTR amyloidosis shows a more transmural enhancement pattern with frequent biventricular involvement than AL amyloidosis, which shows a subendocardial enhancement pattern (<xref rid="B6" ref-type="bibr">6</xref>). Intensely diffuse myocardial retention of <sup>99m</sup>Tc-pyrophosphate has been observed in patients with ATTR amyloidosis compared to those with AL amyloidosis (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B9" ref-type="bibr">9</xref>). The findings in the current case are consistent with these characteristics of ATTR amyloidosis. Recently, Minamisawa et al. demonstrated that patients with wild-type ATTR were characterized by a lower left ventricular ejection fraction and left ventricular radial strains than patients with mutant ATTR, indicating the utility of echocardiography for distinguishing between wild-type ATTR and mutant ATTR (<xref rid="B10" ref-type="bibr">10</xref>).</p>
      <p>Treatment for ATTR type FAP includes liver transplantation and stabilizers of transthyretin tetramers. However, liver transplantation failed to prevent progression of cardiac amyloidosis in ATTR type FAP patients (<xref rid="B11" ref-type="bibr">11</xref>) due to the continued formation of wild-type ATTR derived from the transplanted normal liver graft (<xref rid="B12" ref-type="bibr">12</xref>). Furthermore, patients with late-onset ATTR type FAP are generally contra-indicated for liver transplantation due to their age. Tetrameric transthyretin itself is nonamyloidogenic, but the dissociation of tetramers into compact non-native monomers with low conformational stability can lead to amyloid fibril formation (<xref rid="B13" ref-type="bibr">13</xref>). Tafamidis, which stabilizes transthyretin tetramers, has been approved in Europe and Japan for treatment of adult FAP patients with early symptomatic polyneuropathy to delay neurological impairment (<xref rid="B14" ref-type="bibr">14</xref>). The therapeutic effect of tafamidis on cardiac ATTR amyloidosis remains to be elucidated (<xref rid="B15" ref-type="bibr">15</xref>).</p>
      <p>In conclusion, we observed latent progressive conduction disturbance which appeared to be a feature of late-onset ATTR type FAP associated with Val30Met. At this point, there are therapeutic options for ATTR type FAP which should be initiated earlier. Therefore, careful observation for any subtle changes in the periodic ECGs and consultation with a cardiologist to identify any early changes are important for making a timely differential diagnosis.</p>
    </sec>
    <sec>
      <title>The authors state that they have no Conflict of Interest (COI).</title>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Misu</surname><given-names>K</given-names></name>, <name><surname>Hattori</surname><given-names>N</given-names></name>, <name><surname>Nagamatsu</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan</article-title>. <source>Brain</source>
<volume>122</volume>: <fpage>1951</fpage>-<lpage>1962</lpage>, <year>1999</year>.<pub-id pub-id-type="pmid">10506096</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rapezzi</surname><given-names>C</given-names></name>, <name><surname>Merlini</surname><given-names>G</given-names></name>, <name><surname>Quarta</surname><given-names>CC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types</article-title>. <source>Circulation</source>
<volume>120</volume>: <fpage>1203</fpage>-<lpage>1212</lpage>, <year>2009</year>.<pub-id pub-id-type="pmid">19752327</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takigawa</surname><given-names>M</given-names></name>, <name><surname>Hashimura</surname><given-names>K</given-names></name>, <name><surname>Ishibashi-Ueda</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Annual electrocardiograms consistent with silent progression of cardiac involvement in sporadic familial amyloid polyneuropathy: a case report</article-title>. <source>Intern Med</source>
<volume>49</volume>: <fpage>139</fpage>-<lpage>144</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20075578</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>S</given-names></name></person-group>
<article-title>Cardiac amyloidosis: heterogenous pathogenic backgrounds</article-title>. <source>Intern Med</source>
<volume>43</volume>: <fpage>1107</fpage>-<lpage>1114</lpage>, <year>2004</year>.<pub-id pub-id-type="pmid">15645642</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takei</surname><given-names>Y</given-names></name>, <name><surname>Hattori</surname><given-names>T</given-names></name>, <name><surname>Tokuda</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Senile systemic amyloidosis starting as bilateral carpal and left ulnar tunnel syndrome</article-title>. <source>Intern Med</source>
<volume>42</volume>: <fpage>1050</fpage>-<lpage>1051</lpage>, <year>2003</year>.<pub-id pub-id-type="pmid">14606726</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dungu</surname><given-names>JN</given-names></name>, <name><surname>Anderson</surname><given-names>LJ</given-names></name>, <name><surname>Whelan</surname><given-names>CJ</given-names></name>, <name><surname>Hawkins</surname><given-names>PN</given-names></name></person-group>
<article-title>Cardiac transthyretin amyloidosis</article-title>. <source>Heart</source>
<volume>98</volume>: <fpage>1546</fpage>-<lpage>1554</lpage>, <year>2012</year>.<pub-id pub-id-type="pmid">22888163</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buxbaum</surname><given-names>J</given-names></name>, <name><surname>Anan</surname><given-names>I</given-names></name>, <name><surname>Suhr</surname><given-names>O</given-names></name></person-group>
<article-title>Serum transthyretin levels in Swedish TTR V30M carriers</article-title>. <source>Amyloid</source>
<volume>17</volume>: <fpage>83</fpage>-<lpage>85</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20462367</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Gameren</surname><given-names>II</given-names></name>, <name><surname>Hazenberg</surname><given-names>BP</given-names></name>, <name><surname>Bijzet</surname><given-names>J</given-names></name>, <name><surname>van Rijswijk</surname><given-names>MH</given-names></name></person-group>
<article-title>Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice</article-title>. <source>Arthritis Rheum</source>
<volume>54</volume>: <fpage>2015</fpage>-<lpage>2021</lpage>, <year>2006</year>.<pub-id pub-id-type="pmid">16732553</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bokhari</surname><given-names>S</given-names></name>, <name><surname>Casta&#xF1;o</surname><given-names>A</given-names></name>, <name><surname>Pozniakoff</surname><given-names>T</given-names></name>, <name><surname>Deslisle</surname><given-names>S</given-names></name>, <name><surname>Latif</surname><given-names>F</given-names></name>, <name><surname>Maurer</surname><given-names>MS</given-names></name></person-group>
<article-title><sup>99m</sup>Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from transthyretin-related familial and senile cardiac amyloidoses</article-title>. <source>Circ Cardiovasc Imaging</source>
<volume>6</volume>: <fpage>195</fpage>-<lpage>201</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23400849</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Minamisawa</surname><given-names>M</given-names></name>, <name><surname>Koyama</surname><given-names>J</given-names></name>, <name><surname>Sekijima</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Comparison of the standard and speckle tracking echocardiographic features of wild-type and mutated transthyretin cardiac amyloidoses</article-title>. <source>Eur Heart J Cardiovasc Imaging</source>
<volume>17</volume>: <fpage>402</fpage>-<lpage>410</lpage>, <year>2016</year>.<pub-id pub-id-type="pmid">26873458</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olofsson</surname><given-names>BO</given-names></name>, <name><surname>Backman</surname><given-names>C</given-names></name>, <name><surname>Karp</surname><given-names>K</given-names></name>, <name><surname>Suhr</surname><given-names>OB</given-names></name></person-group>
<article-title>Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type</article-title>. <source>Transplantation</source>
<volume>73</volume>: <fpage>745</fpage>-<lpage>751</lpage>, <year>2002</year>.<pub-id pub-id-type="pmid">11907421</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ihse</surname><given-names>E</given-names></name>, <name><surname>Suhr</surname><given-names>OB</given-names></name>, <name><surname>Hellman</surname><given-names>U</given-names></name>, <name><surname>Westermark</surname><given-names>P</given-names></name></person-group>
<article-title>Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis</article-title>. <source>J Mol Med</source>
<volume>89</volume>: <fpage>171</fpage>-<lpage>180</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21107516</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ueda</surname><given-names>M</given-names></name>, <name><surname>Ando</surname><given-names>Y</given-names></name></person-group>
<article-title>Recent advances in transthyretin amyloidosis therapy</article-title>. <source>Transl Neurodegener</source>
<volume>3</volume>: <fpage>19</fpage>, <year>2014</year>.<pub-id pub-id-type="pmid">25228988</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coelho</surname><given-names>T</given-names></name>, <name><surname>Maia</surname><given-names>LF</given-names></name>, <name><surname>da Silva</surname><given-names>AM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy</article-title>. <source>J Neurol</source>
<volume>260</volume>: <fpage>2802</fpage>-<lpage>2814</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23974642</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maurer</surname><given-names>MS</given-names></name>, <name><surname>Grogan</surname><given-names>DR</given-names></name>, <name><surname>Judge</surname><given-names>DP</given-names></name>, <etal>et al</etal></person-group>
<article-title>Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes</article-title>. <source>Circ Heart Fail</source>
<volume>8</volume>: <fpage>519</fpage>-<lpage>526</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">25872787</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
